Here are relevant reports on : poultry-medicine-market
-
Nucleic Acid Isolation and Purification Market by Product (Kits, Reagents, Instruments), Method (Column, Magnetic Beads), Type (Genomic DNA, Plasmid DNA), Application (Diagnostics, Personalized Medicine), End User (CROs), Region - Global Forecast to 2030
The global nucleic acid isolation and purification market, valued at US$6.67 billion in 2024, stood at US$7.10 billion in 2025 and is projected to advance at a resilient CAGR of 9.1% from 2025 to 2030, culminating in a forecasted valuation of US$10.99 billion by the end of the period. The global market for nucleic acid isolation and purification (NAIP) is expanding largely due to the increased use of PCR and NGS in clinical diagnostics and research. Laboratories globally require DNA/RNA of high purity and free of inhibitors in order to carry out reliable workflows for sequencing, oncology panels and routine molecular testing.
- Published: January 2026
- Price: $ 4950
- TOC Available:
-
Precision Medicine Software Market by Delivery Mode (On-Premise & Cloud-Based), End User (Healthcare Providers, Research Centers & Government Institutes, Pharmaceutical & Biotechnology Companies), Application, and Region - Global Forecast to 2024
The precision medicine software market is projected to reach USD 2.0 billion by 2024, at a CAGR of 11.5%. Factors such as the rising government funding in precision medicine initiatives, partnerships among pharmaceutical and software companies, the entry of new players & VC funding, and growth in the number of cancer patients are driving the growth of the precision medicine software market. However, the high cost of deployment, issues related to the secure storage of large volumes of sequenced data, lack of reimbursement for precision medicine-based treatments, and the dearth of skilled IT professionals in healthcare are expected to restrain market growth to a certain extent in the coming years. Syapse, Inc. (US), 2bPrecise LLC (Israel), Foundation Medicine, Inc. (US), Fabric Genomics (US), SOPHiA GENETICS SA (Switzerland), PierianDx, Inc. (US), N-of-One, Inc. (US), Human Longevity, Inc. (US), Translational Software, Inc. (US), Sunquest Information Systems Inc. (US), Gene42, Inc. (Canada), LifeOmic Health, LLC (US), NantHealth, Inc. (US), Tempus Labs, Inc. (US), Flatiron Health, Inc. (US), IBM Watson Group (US), and Koninklijke Philips N.V. (Netherlands)
- Published: March 2019
- Price: $ 4950
- TOC Available:
-
Pharmacogenomics Market by Product & Service (Kits & Reagents), Technology (Sequencing, PCR, Microarray), Application (Drug Discovery, Clinical Research, Personalized Medicine), Disease Area (Cancer, Neurological, Cardiovascular) - Global Forecast to 2028
The global pharmacogenomics market, valued at US$3.3 billion in 2022, stood at US$3.5 billion in 2023 and is projected to advance at a resilient CAGR of 10.6% from 2023 to 2028, culminating in a forecasted valuation of US$5.8 billion by the end of the period. The increasing focus on the translational approach to optimize drug development processes, increasing collaborations and partnerships between key players and research institutes, and rising incidence of cancer are the major driving factors of the pharmacogenomics market.
- Published: February 2024
- Price: $ 4950
- TOC Available:
-
Molecular Cytogenetics Market by Product (Kits, Reagents, Probes, Instrument, Software, Services), Technique (FISH, CISH, Comparative Genomic Hybridization [Array-based, Standard]), Application (Cancer, Personalized Medicine) - Global Forecast to 2030
The global molecular cytogenetics market, valued at US$0.97 billion in 2024, stood at US$1.02 billion in 2025 and is projected to advance at a resilient CAGR of 7.1% from 2024 to 2030, culminating in a forecasted valuation of US$1.43 billion by the end of the period. The market growth is fueled by increasing incidence of cancer & genetic disorders and rising usage of molecular cytogenetics in clinical pathology testing.
- Published: October 2025
- Price: $ 4950
- TOC Available:
-
Cell Line Development Market by Product (Equipment, Media and Reagents), Source, type & by Application ( Bioproduction, Tissue Engineering & Regenerative medicine, Toxicity Testing, Research, Drug Discovery) - Analysis & Global Forecast to 2019
The global cell line development market is expected to reach 3.96 billion by 2019 from $2.2 billion in 2014, and is expected to grow at a CAGR of 12.5% from 2014 to 2019. The market is dominated by North America, followed by Europe, Asia, and Rest of the World (RoW). North America is expected to maintain its leadership position in the market in the coming years.
- Published: September 2014
- Price: $ 4950
- TOC Available:
-
Europe Nucleic Acid Isolation and Purification Market by Product (Kits, Reagents, Instruments), Method (Column, Magnetic Beads), Type (Genomic DNA, Plasmid DNA, mRNA), Application (Diagnostics, Personalized Medicine), End User (CROs) - Forecast to 2030
The Europe nucleic acid isolation and purification market, valued at US$1.52 billion in 2024, stood at US$1.61 billion in 2025 and is projected to advance at a resilient CAGR of 8.4% from 2025 to 2030, culminating in a forecasted valuation of US$2.41 billion by the end of the period. The growth of the Europe nucleic acid isolation and purification market is strongly linked to the region’s high volume of molecular tests and the steady adoption of PCR- and NGS-based workflows.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
AI in Precision Medicine Market by Application (Drug Discovery, Screening, Diagnosis, Stratification, Staging, Prognosis, Therapy Selection, Monitoring, Risk Management), Indication (Cancer, CNS, CVS), Tools (ML, NLP), & End User -Global Forecast to 2030
The global AI in Precision Medicine market, valued at US$0.60 billion in 2023, stood at US$0.78 billion in 2024 and is projected to advance at a resilient CAGR of 30.7% from 2024 to 2030, culminating in a forecasted valuation of US$3.92 billion by the end of the period. Growth in precision medicine, AI’s efficiency in drug discovery, integration of Real-World Evidence (RWE) in emerging markets to drive the market significantly.
- Published: November 2024
- Price: $ 4950
- TOC Available:
-
Europe Artificial Intelligence (AI) in Healthcare Market by Offering (Integrated), Function (Diagnosis, Genomic, Precision Medicine, Radiation, Telehealth, RPM, Immunotherapy, Supply Chain), Application (Clinical), End User (Hospitals) - Forecast to 2030
The Europe Artificial Intelligence (AI) in Healthcare Market, valued at USD 4.20 billion in 2024, stood at USD 6.12 billion in 2025 and is projected to advance at a resilient CAGR of 39.0% from 2025 to 2030, culminating in a forecasted valuation of USD 31.72 billion by the end of the period. This growth is driven by strong regulatory support for digital transformation and the rising adoption of AI-enabled clinical workflows across European health systems.
- Published: December 2025
- Price: $ 4950
- TOC Available:
-
Human Organoids Market by Product (Liver, Kidney, Pancreatic Models (2D, 3D)), Disease Area (Oncology, GI, Neurological Disorders), Application (Drug Toxicity, Personalized Medicine), End User (Pharma & Biotech Companies, CROs) - Global Forecast to 2029
The global human organoids market, valued at US$1.07 billion in 2023, stood at US$1.19 billion in 2024 and is projected to advance at a resilient CAGR of 14.4% from 2024 to 2029, culminating in a forecasted valuation of US$2.33 billion by the end of the period. The main factor driving this market is the rising demand for organoids in drug testing, as they provide more reliable results than conventional 2D cell cultures.
- Published: December 2024
- Price: $ 4950
- TOC Available:
-
3D Bioprinting Market by Component (3D bioprinters (Microextrusion, Inkjet, Laser), Bioinks, Software, Consumable), Material (Hydrogels, ECM), Application (Research (Regenerative Medicine, 3D cell Culture), Clinical (Skin, Bone)) - Global Forecast to 2029
The global 3D bioprinting market, valued at US$1.2 billion in 2023, stood at US$1.3 billion in 2024 and is projected to advance at a resilient CAGR of 12.7% from 2024 to 2029, culminating in a forecasted valuation of US$2.4 billion by the end of the period. The market growth is fueled by the growing adoption of 3D bioprinting technology in the pharmaceutical and cosmetic industries, technological advancements in 3D bioprinting, and the rising demand for organ transplants.
- Published: May 2024
- Price: $ 4950
- TOC Available:
Records 11 to 20 of 50
